<table>
<thead>
<tr>
<th>General</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Identification</td>
<td></td>
</tr>
<tr>
<td>Detailed name</td>
<td>Knee and Hip Osteoarthritis Long Term Assessment Cohort</td>
</tr>
<tr>
<td>Sign or acronym</td>
<td>KHOALA</td>
</tr>
<tr>
<td>CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation</td>
<td>CNIL : 906297, CPP : 2006-A00587-44 (17.01.01), Afssaps : 2006-0146</td>
</tr>
<tr>
<td>Medical area</td>
<td>Rheumatology</td>
</tr>
<tr>
<td>Keywords</td>
<td>Prosthesis, quality of life, healthcare usage</td>
</tr>
<tr>
<td>Collaborations</td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>Mixed</td>
</tr>
<tr>
<td>Funding status</td>
<td>Inserm, CHU de NANCY, Société Française de Rhumatologie, InVS, CNAM Firmes industrielles</td>
</tr>
<tr>
<td>Governance of the database</td>
<td>CHU Nancy</td>
</tr>
<tr>
<td>Sponsor(s) or organisation(s) responsible</td>
<td>Public</td>
</tr>
<tr>
<td>Organisation status</td>
<td>Yes</td>
</tr>
<tr>
<td>Presence of scientific or steering committees</td>
<td></td>
</tr>
<tr>
<td>Scientific investigator(s) (Contact)</td>
<td>GUILLEMIN</td>
</tr>
<tr>
<td>Name of the director</td>
<td></td>
</tr>
</tbody>
</table>
Main features

Type of database

Study databases

Cohort study

Database recruitment is carried out by an intermediary

A selection of health institutions and services

No

Additional information regarding sample selection.

Database objective

Main objective

General objective: To describe the natural history of symptomatic hip and knee osteoarthritis and to identify predictive factors of its consequences in terms of pain, functional incapacity, quality of life and healthcare (medical care, use of healthcare resources and illness cost). Patients for this cohort study are identified during a national prevalence study. Secondary objectives: - to investigate predictive factors for quality of life, changes in quality of life and hip or knee replacement such as: socio-demographic parameters, clinical factors, comorbidities, perceived health parameters at baseline (quality of life, functional capacity), x-rays and biological markers; - to identify factors that influence healthcare usage, social impact and treatment for symptomatic hip and knee osteoarthritis; - to collect and store biological samples (serum bank...
and DNA bank), x-rays, clinical and perceived health data in order to form a platform for other research projects, such as physiopathological projects on cellular and molecular mechanisms of osteoarthritis and genetic projects. This cohort will benefit from the advantages of the descriptive prevalence study and will allow the recruitment of a general population based representative sample.

**Inclusion criteria**

- Men and women between 40 and 75 years of age
- Symptomatic uni- or bilateral knee (tibio-femoral) and hip osteoarthritis with confirmed diagnosis that meets EULAR and ACR criteria, identified from prevalent cases in France during cohort formation

**Population type**

- Adulthood (45 to 64 years)
- Elderly (65 to 79 years)

**Population covered**

- Sick population

**Gender**

- Male
- Woman

**Geography area**

- National

**French regions covered by the database**

- Alsace Champagne-Ardenne Lorraine
- Bretagne
- Île-de-France
- Languedoc-Roussillon Midi-Pyrénées
- Nord - Pas-de-Calais Picardie
- Provence - Alpes - Côte d'Azur

**Detail of the geography area**

- Multicentric cohort throughout France (6 centres)

**Data collection**

**Dates**

- Date of first collection (YYYY or MM/YYYY): 04/2007
- Date of last collection (YYYY or MM/YYYY): 04/2019

**Size of the database (number of individuals)**

- [500-1000] individuals
Details of the number of individuals

Data

Database activity

Type of data collected

Clinical data (detail)

Declarative data (detail)

Paraclinical data (detail)

Biological data (detail)

Presence of a biobank

Contents of biobank

Details of biobank content

Health parameters studied

Procedures

Data collection method

Participant monitoring

Monitoring procedures

Details on monitoring of participants

Links to administrative sources

---

### Details of the number of individuals

878

### Data

#### Database activity

Current data collection

- Clinical data
- Declarative data
- Paraclinical data
- Biological data

#### Type of data collected

- Clinical data
  - Direct physical measures
  - Medical registration
- Declarative data
  - Paper self-questionnaire
  - Face to face interview
- Paraclinical data
  - Imaging
- Biological data
  - DNA, urine, serum samples

#### Presence of a biobank

Yes

#### Contents of biobank

- Serum
- Fluids (saliva, urine, amniotic fluid, ?)
- DNA

#### Details of biobank content

- Serum bank, DNA bank, urine

#### Health parameters studied

- Health event/morbidity
- Health event/mortality

#### Procedures

- Self-administered questionnaire: input from a paper questionnaire
- Interviews: input from a paper questionnaire
- Clinical examinations: handwritten.

#### Participant monitoring

Yes

#### Monitoring procedures

- Monitoring by contact with the participant (mail, e-mail, telephone etc.)
- Monitoring by convocation of the participant
- Monitoring by contact with the referring doctor

#### Details on monitoring of participants

Follow-up duration: 10 years

#### Links to administrative sources

No
<table>
<thead>
<tr>
<th>Promotion and access</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Promotion</strong></td>
</tr>
<tr>
<td><strong>Link to the document</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>List of publications in HAL</strong></td>
</tr>
<tr>
<td><strong>Link to the document</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>List of publications in Pubmed</strong></td>
</tr>
<tr>
<td><strong>Access</strong></td>
</tr>
<tr>
<td><strong>Presence of document that lists variables and coding procedures</strong></td>
</tr>
<tr>
<td><strong>Terms of data access (charter for data provision, format of data, availability delay)</strong></td>
</tr>
<tr>
<td><strong>Data may be used by academic teams Access conditions: networks working with UMR 7561 physiopathology, pharmacology and joint engineering pharmacology laboratory, Vandœuvre-lès-Nancy. Collaboration with external teams is planned. Access to the constructed database is permitted by a partnership charter, which has been developed and already exhibited, mainly to potential partners, during communication concerning the cohort at the French Rheumatology Congress in 2008. Data may not be used by industrial teams.</strong></td>
</tr>
<tr>
<td><strong>Access to aggregated data</strong></td>
</tr>
<tr>
<td><strong>Access to individual data</strong></td>
</tr>
</tbody>
</table>